Nathalie Bonnefoy, cofounder of OREGA Biotech and deputy director of Institut de Recherche en Cancérologie de Montpellier (IRCM), will inaugurate the first CyTOF Hyperion in France on September 18, 2019 at IRCM. Equipped with a very innovative technology, the CyTOF Hyperion will make it possible to explore tumor heterogeneity from a biopsy by very finely mapping tumor cells in their microenvironment, including the interactions with and between the immune cells. The CyTOF is a powerful tool for immuno-oncology studies. It reveals the structure of disease tissue at the single cell level and enables the characterization with up to 50 markers, from a single slide, of the spatial distribution and the cellular network with immune cells.
The publication of preclinical data of the CD39-blocking monoclonal antibody IPH5201 appears in the May 21, 2019 issue of the journal Cell Reports. Read the full manuscript titled “Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies”